The Maudsley Prescribing Guidelines in Psychiatry - Allan H. Young

. .

Résumé :

Preface xi
Acknowledgements xiii
Contributors' conflict of interest xv
List of abbreviations xvii

Chapter 1 Schizophrenia and related psychoses 1

Antipsychotic Drugs 1
General introduction 1
General principles of prescribing 7
Antipsychotics - minimum effective doses 8
Quick reference for licensed maximum doses 11
Equivalent doses 14
High- dose antipsychotic medication: prescribing and monitoring 17
Combined antipsychotics (antipsychotic polypharmacy) 22
Antipsychotic prophylaxis 28
Negative symptoms 34
Monitoring 40
Relative adverse effects - a rough guide 43
Treatment algorithms for schizophrenia 45
First- generation antipsychotics - place in therapy 49
NICE guidelines for the treatment of schizophrenia 52
Antipsychotic response - to increase the dose, to switch, to add or just wait - what is the right move? 55
Acutely disturbed or violent behaviour 62
Antipsychotic depots/long- acting injections 74
Depot antipsychotics - summary of pharmacokinetics 81
Management of patients on long- term treatment with long- acting injectable antipsychotic medication 83
Aripiprazole long- acting injection 85
Olanzapine long- acting injection 90
Paliperidone palmitate long- acting injection 93
Risperidone long- acting injection 99
Penfluridol weekly 106
Electroconvulsive therapy and psychosis 108
Omega- 3 fatty acid (fish oils) in schizophrenia 111
Alternative routes of administration 115
Stopping antipsychotics 119
Antipsychotic Adverse Effects 126
Extrapyramidal symptoms 126
Akathisia 131
Treatment of tardive dyskinesia 135
Antipsychotic- induced weight gain 141
Treatment of antipsychotic- induced weight gain 144
Neuroleptic malignant syndrome 150
Catatonia 154
ECG changes - QT prolongation 161
Effects of antipsychotic medications on plasma lipids 169
Diabetes and impaired glucose tolerance 174
Blood pressure changes with antipsychotics 182
Antipsychotic- associated hyponatraemia 186
Hyperprolactinaemia 190
Sexual dysfunction and antipsychotics 195
Pneumonia 204
Switching antipsychotics 207
Venous thromboembolism 211
Refractory Schizophrenia and Clozapine 214
Clozapine initiation schedules 214
Intramuscular clozapine 219
Optimising clozapine treatment 220
Alternatives to clozapine 226
Restarting clozapine after a break in treatment 234
Initiation of clozapine in the community 236
Clozapine Adverse Effects 241
Clozapine: common adverse effects 241
Clozapine: uncommon or unusual adverse effects 245
Clozapine: serious haematological adverse effects 251
Clozapine: serious cardiovascular adverse effects 253
Clozapine- induced hypersalivation 258
Clozapine- induced gastrointestinal hypomotility 263
Clozapine, neutropenia and lithium 267
Clozapine and chemotherapy 273
Genetic testing for clozapine treatment 275

Chapter 2 Bipolar disorder 279

Lithium 279
Valproate 289
Carbamazepine 295
Antipsychotic drugs in bipolar disorder 300
Antipsychotic long- acting injections in bipolar disorder 305
Physical monitoring for people with bipolar disorder 308
Treatment of acute mania or hypomania 310
Rapid- cycling bipolar affective disorder 316
Bipolar depression 319
Prophylaxis in bipolar disorder 326
Stopping lithium and mood stabilisers 331

Chapter 3 Depression and anxiety disorders 335

Introduction to depression 335
Antidepressants - general overview 337
Recognised minimum effective doses of antidepressants 342
Drug treatment of depression 344
Management of treatment-resistant depr...

Biographie:

David M. Taylor is Director of Pharmacy and Pathology at the Maudsley Hospital and Professor of Psychopharmacology at King's College, London.

Thomas R. E. Barnes Emeritus Professor of Clinical Psychiatry at Imperial College London and joint head of the Prescribing Observatory for Mental Health at the Royal College of Psychiatrists' Centre for Quality Improvement, London, UK.

Allan H. Young Chair of Mood Disorders and Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King's College, London, UK....

Sommaire:

David M. Taylor, BSc, MSc, PhD, FFRPS, FRPharmS, FRCPEdin, FRCPsychHon, is Director of Pharmacy and Pathology at the Maudsley Hospital and Professor of Psychopharmacology at King's College, London.

Thomas R. E. Barnes, MBBS, MD, FRCPsych, DSc, Emeritus Professor of Clinical Psychiatry at Imperial College London and joint head of the Prescribing Observatory for Mental Health at the Royal College of Psychiatrists' Centre for Quality Improvement, London, UK.

Allan H. Young, MB, ChB, MPhil, PhD, FRCP, FRCPsych, Chair of Mood Disorders and Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King's College, London, UK.